- ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
This early-stage study is testing a new combination of medicines, AB308 and AB122, for people with several types of advanced cancer, including blood cancers and solid tumours. It aims to see if the treatment is safe and how the body reacts to it.
Spain · Poland - recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - not yet recruiting
The Microbiome in Blood Cancer and HLH
This study looks at how gut bacteria and viruses, called the microbiome, affect people with certain blood cancers and a severe inflammatory condition called HLH. Researchers want to better understand how these tiny organisms influence treatment response and side effects, aiming to improve future care.
United Kingdom - recruitingPHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study compares a new drug, odronextamab, with standard treatment for a type of lymphoma called DLBCL. It looks at how well they work with chemotherapy and their safety in adults who haven't been treated before, or whose lymphoma has come back.
United States · Australia · Austria - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This early-stage study is looking at a new combination of existing and new drugs for people with certain types of lymphoma, including Diffuse Large B-cell Lymphoma (DLBCL). It aims to check if this new treatment is safe and how well it works.
Spain · France · Italy - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
This study is looking at new ways to treat Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer. Researchers are testing a drug called mosunetuzumab, by itself or with another drug, polatuzumab vedotin. The aim is to see how well these treatments work and if they are safe.
Spain · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
This study looks at a new drug, BAY 80-6946, with standard chemotherapy for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's in an early stage (Phase 2), focusing on finding the best dose and checking if the treatment is safe and effective.
Germany